This is similar to the mechanism by which caplacizumab, the only TTP-specific therapeutic agent, binds to the A1 domain of vWF, thus stopping the chain of events that leads to platelet binding and subsequent thrombocytopenia [99,100]. Here, VWF is linked to Thrombocytopenia.